The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Abstract
To the Editor: With regard to the article by Wainwright et al. (July 16 issue),1 randomized trials evaluating the efficacy of lumacaftor, ivacaftor, or both have included only a limited number of patients with a forced expiratory volume in 1 second (FEV1) at baseline of less than 40% of the predicted value. Only 52 patients in the TRAFFIC and TRANSPORT trials and none of the patients in several other studies had this low percentage of predicted FEV1 at baseline. 2,3 Since the majority of patients in resource-limited countries receive a diagnosis of cystic fibrosis later in childhood (when the disease might be advanced), the efficacy of lumacaftor–ivacaftor therapy in patients with poor pulmonary function needs to be evaluated further. Moreover, the current cost of lumacaftor–ivacaftor therapy is almost $300,000 per year; this is much higher than the cost of conventional therapy, which is less than $300 per year. Since the magnitude of change observed with lumacaftor– ivacaftor therapy was “in the range of the magnitudes of change seen in studies of other cystic fibrosis therapeutics,”1 the cost-effectiveness of this form of therapy should be evaluated.4 Finally, in some regions of the world, the Phe508del CFTR mutation is uncommon (e.g., one study5 showed that only 26.9% of patients with cystic fibrosis in the United Arab Emirates are homozygous for this allele). For these patients, conventional therapy (hypertonic saline, azithromycin, or ibuprofen) remains the treatment of choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
Flume, P. A., Liou, T. G., Borowitz, D. S., Li, H., Yen, K., Ordoñez, C. L., & Geller, D. E. (2012) · Chest · doi:10.1378/chest.11-2672 · Cited by 338
Cited by
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
Berkers, G., van Mourik, P., Vonk, A. M., Kruisselbrink, E., Dekkers, J. F., de Winter-de Groot, K. M., Arets, H. G. M., Marck-van der Wilt, R. E. P., Dijkema, J. S., Vanderschuren, M. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.068 · Cited by 310
Structural identification of a hotspot on CFTR for potentiation
Liu, F., Zhang, Z., Levit, A., Levring, J., Touhara, K. K., Shoichet, B. K., & Chen, J. (2019) · Science · doi:10.1126/science.aaw7611 · Cited by 253
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-10-29
- Volume
- 373
- Issue
- 18
- Pages
- 1783-1784
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3140132982
- Cited by
- 179
- References
- 2
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. https://app.cochat.ai/papers/10.1056/nejmc1510466
- The paper
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. (2015). New England Journal of Medicine. https://doi.org/10.1056/nejmc1510466
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.